AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation

• Status: Terminated
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized trial of low-dose amiodarone therapy versus catheter ablation (CA) in older patients with persistent atrial fibrillation (AF).

Primary Objective: To compare amiodarone to catheter ablation in patients aged 50 to 80 years with symptomatic AF for the composite outcome of hospitalization for cardiovascular cause or emergency department visit for atrial arrhythmia

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guy Amit; Population Health Research Institute
• Collaborators: Hamilton Health Sciences Corporation; Population Health Research Institute
• Treatments: Amiodarone; Anti-Arrhythmia Agents

Criteria

Inclusion Criteria:

1. Recurrent symptomatic Atrial Fibrillation (AF)

2. Age 50-80 years with persistent AF (≥1 of AF episode lasting more than a week or requiring cardioversion)

Exclusion Criteria:

1. Permanent atrial fibrillation

2. Prior continuous use of amiodarone of more than 2 weeks.

3. Prior catheter ablation for AF.

4. Have a documented resting heart (while awake) of < 50 beats per minute.

5. Have a known severe liver disease.

6. Are deemed not suitable for CA (LA size, comorbidities…).

7. Have a severe valvular disease or have a mechanical mitral prosthesis.

8. Have a life-expectancy of less than 2 years.